Table 1. Differential expressions of miRNAs in Long Survival versus Short Survival Group were analyzed by miRNA microarray analysis.
| Short Survival Group | Long Survival Group | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| miRNA | Normalized | SD | Normalized | SD | Fold | Type | Function | Tissue type | Ref. |
| hsa-miR-125a-5p | 0.05 | 0.08 | 1.95 | 0.02 | 0.03 | down | low expression in cancer | Breast cancer | Iorio et al., 2005 |
| hsa-miR-206 | 1.64 | 0.06 | 0.07 | 0.03 | 24.37 | up | Unknown | ||
| hsa-miR-146b-3p | 0.2 | 0.13 | 3.93 | 0.06 | 0.05 | down | Unknown | ||
| hsa-miR-518a-3p | 0.44 | 0.07 | 0.03 | 0.02 | 16.97 | up | Unknown | ||
| hsa-miR-193a-5p | 1.91 | 0.05 | 0.13 | 0.06 | 14.88 | up | Unknown | ||
| hsa-miR-155 | 3.73 | 0.04 | 0.38 | 0.07 | 9.85 | up | correlated with poor survival | Lung cancer | Yanaihara et al., 2006 |
| hsa-miR-181c | 1.2 | 0.08 | 10.31 | 0.09 | 0.12 | down | regulates TNF-α expression | Hepatocellular | Río et al., 2012 |
| hsa-miR-520c-3p | 0.07 | 0.05 | 0.63 | 0.07 | 0.12 | down | Unknown | ||
| hsa-miR-30a | 4.96 | 3.54 | 0.64 | 0.15 | 7.71 | up | correlated with poor survival | Hepatocellular | Budhu et al., 2008 |
| hsa-miR-181b | 0.08 | 0.09 | 0.63 | 0.04 | 0.13 | down | enhances drug sensitivity | Leukemia | Zhu et al., 2012 |
| hsa-miR-503 | 24.03 | 0.07 | 3.15 | 0.06 | 7.63 | up | regulates partial differentiation | Leukemia | Forrest et al., 2010 |
| hsa-let-7b | 0.02 | 0.05 | 0.12 | 0.02 | 0.15 | down | regulates proliferation and apoptosis | Liver cancer | Di Fazio et al., 2012 |
| hsa-let-7a | 0.16 | 0.07 | 0.98 | 0.02 | 0.16 | down | correlated with poor survival | Lung cancer | Yanaihara et al., 2006 |
| hsa-miR-134 | 0.21 | 0.06 | 1.25 | 0.20 | 0.17 | down | Unknown | ||
| hsa-miR-486-5p | 0.91 | 0.06 | 4.37 | 0.05 | 0.21 | down | Unknown | ||
| hsa-miR-21 | 0.45 | 0.04 | 0.09 | 0.03 | 4.77 | up | correlated with poor survival | Lung carcinoma | Gao et al., 2011 |
| hsa-miR-205 | 7.82 | 0.09 | 1.77 | 0.05 | 4.41 | up | highly accurate marker for lung cancer | Lung carcinoma | Lebanony et al., 2009 |
| hsa-miR-218 | 0.12 | 0.09 | 0.5 | 0.20 | 0.25 | down | inhibits invasion and metastasis | Gastric cancer | Tie et al., 2010 |
| hsa-miR-194 | 0.93 | 0.86 | 0.23 | 0.02 | 4.04 | up | promote angiogenesis | Colon cancers | Sundaram et al., 2011 |
| hsa-miR-151-3p | 0.83 | 0.23 | 0.26 | 0.05 | 3.19 | up | increases migration and invasion | Hepatocellular | Ding et al., 2010 |
Short Survival Group: survived for less than 1 year after diagnosis, case number = 5
Long Survival Group: survived for more than 5 years after diagnosis, case number = 5
Normalized: 2^-Δct, Fold: Short/Long